Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure

Posted On: 2020-11-23 01:50:32 (Time Zone: Arizona, USA)


The oral antiviral medication Favipiravir, that prevents the replication phase of the virus life-cycle, leads to significant improvement in clinical cure in patients with mild to moderate COVID-19. These findings were observed in a randomized, controlled Phase 3 clinical study conducted by Glenmark Pharmaceuticals, and the results are now published online in The International Journal of Infectious Diseases (IJID). The IJID is a globally reputed, peer-reviewed, pubmed indexed, open access journal published monthly by the International Society for Infectious Diseases, USA. The published findings will also appear in the print edition of the journal in the coming weeks.

The publication on the study titled "Efficacy and Safety of Favipiravir, an Oral RNADependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial" was authored by Dr. Zarir .F. Udwadia and other co-authors.

The link to the article is mentioned below

https://authors.elsevier.com/sd/article/S1201-9712(20)32453-X

https://www.sciencedirect.com/science/article/pii/S120197122032453X

The Phase 3 study with antiviral drug Favipiravir, brand name FabiFlu®, was conducted in 150 patients as part of a randomised, open label, multicenter, Phase 3 study. The study aimed to evaluate the efficacy and safety of Favipiravir plus standard supportive care (Favipiravir treatment arm), versus standard supportive care alone (control arm), in mild to moderate patients, randomized within a 48 hour window of testing RT-PCR positive for COVID-19.

Favipiravir was found to provide multiple treatment benefits, demonstrated by faster time to clinical cure, and significantly delayed the need for supportive oxygen therapy. Additionally, patients of confirmed COVID-19 with moderate symptoms were discharged from hospital earlier than those patients that did not receive Favipiravir, with the median time to clinical cure reduced by 2.5 days compared with the control group.

Dr Zarir F. Udwadia. MD, FRCP, FCCP, Breach Candy Hospital, Mumbai commented "Every claim for the efficacy of a new drug in COVID-19 must be backed by evidence from a clinical trial. Glenmark has done just that with Favipiravir. Their well-designed trial in 150 patients showed Favipiravir resulted in a significantly improved time to clinical cure and rapid viral clearance. Based on this I would consider the use of this anti-viral drug in symptomatic patients with mild to moderate COVID-19. I eagerly await the results of similar trials presently being conducted in Boston and at Stanford".

Since it was first pronounced a pandemic by the WHO in March, COVID-19 has continued to impact the lives of millions of people globally. As of date, over 50 mn. cases have been reported, with over 1 mn. deaths attributed to this disease. The virus has reportedly spread to all around the world and territories across the globe.i Most disease cases are mild to moderate, with symptoms including fever, cough and breathlessness. In severe cases, COVID-19 can cause pneumonia, severe acute respiratory syndrome, kidney failure and death.ii

Favipiravir is an antiviral medication that works by inhibiting a viral enzyme called RdRP (RNA dependent RNA polymerase), thereby halting the virus's replication cycle. This helps control the multiplication of the virus and prevents its spread in the patient. This mechanism of action of Favipiravir is novel compared to most antivirals that primarily prevent entry and exit of the virus from cells. Several published reports are now available of the drug's effectiveness against COVID-19.

Mr. Robert Crockart, Chief Commercial Officer Glenmark Pharmaceuticals said, "From the first reported case of COVID-19, our every effort was to bring a viable, safe and effective treatment option to patients in a timely manner. It is encouraging to see our trial results now published in a reputed global medical journal, which we hope will support other countries in their fight against this disease."

Patients in the Glenmark clinical trial received Favipiravir tablets 3,600 mg (1,800 mg BID) (Day 1) + 1,600 mg (800 mg BID) (Day 2 or later) for up to maximum of 14 days, along with standard supportive care. Randomization was stratified based on disease severity into mild and moderate. Favipiravir was well tolerated with no serious adverse events (SAEs) or deaths in the Favipiravir treated arm.

The pre-specified primary endpoint, time from randomisation to cessation of oral shedding of the SARS-CoV-2 virus, demonstrated a 2 day earlier virological cure in the Favipiravir treatment group, though not statistically significant. However, significant improvement in time to clinical cure and other secondary end-points suggest Favipiravir may be beneficial in the treatment of mild-to-moderate COVID-19.

"The study, which was undertaken by Glenmark Pharmaceuticals, at a time when the number of cases for infections were dramatically increasing around the globe, demonstrates Glenmark's commitment to ensuring all patients have access to affordable medication, to make a positive impact on their quality of life," said Dr. Monika Tandon, Sr. Vice President & Head - Clinical Development, Global Specialty/Branded Portfolio at Glenmark.

In June 2020, Glenmark received manufacturing and marketing approval from India's drug regulator for Favipiravir (FabiFlu®), making it the first oral approved medication in India for the treatment of mild to moderate COVID-19. The manufacturing and marketing approval was granted as part of an accelerated approval process, considering the emergency situation of the COVID-19 outbreak in India. The approval's restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.481.45 as compared to the previous close of Rs. 482.7. The total number of shares traded during the day was 69677 in over 1989 trades.

The stock hit an intraday high of Rs. 486.6 and intraday low of 478.3. The net turnover during the day was Rs. 33565841.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Ind-Ra upgrades Happiest Minds Technologies Limited's Long-Term Issuer Rating

Brickwork reaffirms Dhanlaxmi Bank's rating of Lower Tier-II bonds - Series XV

AGEL commissions 100 MW Gujarat Wind Power Project 5 months before schedule

Meera Industries Limited receives order of $180,000

Atul Auto launches its all new Nxt Gen, Atul RIK CNG Autorickshaw for Gujarat

NATCO receives final approval for Everolimus tablets for the US market

Blue Star declared winner of the prestigious 'Golden Peacock Award for Excellence in Corporate Governance' for 2020

Just Dial enters into an advertisement agreement for IPL

Fortis Hospital, Faridabad extends it services at Mathura, Launches Super Specialty OPD services

Fire accident at Radico Khaitan Ltd's Rampur plant

Adani Ports and SEZ Limited to allot 1 crore shares to Windy Lakeside Invesment Ltd

Hero MotoCorp Limited announces exclusive offer for women riders

Mayukh Dealtrade Ltd board to consider Stock Split of Equity Shares

CARE downgrades ratings of Srei Infrastructure Finance Limited to default category

Shish Industries Limited forms subsidiary

Dhani Services Limited board approves sponsored Level III ADR

Prakash Steelage Ltd board approves sale of shares of Tubacex Prakash India Pvt Ltd

Sayaji Hotels Management Ltd enters into management agreement for 7 properties

GRSE Lays Keel of 3rd Ship of Prestigious Project 17A Advanced Stealth Frigate

NMDC revises prices of iron ore w.e.f. 06-03-2021

Aarti Speciality Chemicals Limited receives an approval accorded under PLI Scheme for Pharmaceutical Sector

Mawana Sugars Limited approves investment of Rs. 10 crores in Siel Industrial Estate Ltd

TVS Motor Company to provide free COVID-19 vaccination to all employees and their immediate family members

Satyam Silk Mills Ltd board to consider rights issue on March 10, 2021

GRM Overseas Ltd board to consider interim dividend on March 10, 2021

Rushil Decor Limited starts commercial production of MDF board at new Vizag plant

IIFL Securities Ltd board to consider interim dividend on March 10, 2021

DCW Limited allots debentures to Kotak Special Situations Fund

M G George Muthoot, Chairman of Muthoot Finance Limited passes away

Acuite Ratings & Research Limited update on rating of Edelweiss Financial Services Limited

Kotak Mahindra Bank Appoints Dr Ashok Gulati as an Additional Independent Director on its Board

Xanadu Realty ties up with Poddar Housing Development Limited in a mega portfolio deal

Edelweiss Financial Services Limited updates on credit rating of proposed NCD issue

IndiGrid signs the largest power transmission deal with Sterlite Power AUM to leapfrog to over INR 200 Bn

Indian Bank to divest stake in JV, ASREC India Ltd

Dai-ichi Karkaria Limited updates on Kasarwadi Land Deal

AKI India Ltd approves construction of effluent treatment plant

Kotak Silk Launches Eduseries for Financial Independence of Women

Ind-Ra has assigned ratings to JSW Hydro Energy Ltd

Shriram EPC Limited board to consider issue of preference shares to lenders

Suncare Traders Limited to demerge investment division to Madhav Infra Projects Ltd

Astral Poly Technik Limited fixes March 19, 2021 as record date for bonus issue

Mazagon Dock Shipbuilders Limited gifts refrigerated truck

Sandhar Technologies Ltd announces incorporation of step down subsidiary

NMDC LTD. board to consider interim dividend on Mar 11, 2021

CRISIL revises outlook of Canara Bank's long-term debt instruments

Hero MotoCorp launches 4-day special service and exchange carnival

ICICI Lombard General Insurance Company Limited board approves interim dividend of Rs. 4

Sun Pharma arm to acquire stake in WRS Bioproducts Pty Ltd, Australia

Kirloskar Oil Engines Ltd declares interim dividend of Rs. 1.50 for FY21



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020